{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:28:28Z","timestamp":1793978908507,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242199"],"award-info":[{"award-number":["7242199"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173211"],"award-info":[{"award-number":["82173211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119252","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:50:54Z","timestamp":1787241054000},"page":"119252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis and biological evaluation of novel gemcitabine-dexamethasone hybrid as potent antitumor agents against esophageal cancer"],"prefix":"10.1016","volume":"319","author":[{"given":"Ruoxin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.119252_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11912-021-01153-4","article-title":"Update on management of squamous cell esophageal cancer","volume":"24","author":"Waters","year":"2022","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119252_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.119252_bib3","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.22926.1","article-title":"Recent advances in treating oesophageal cancer","volume":"9","author":"Harada","year":"2020","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119252_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","article-title":"Esophageal cancer: risk factors, genetic association, and treatment","volume":"41","author":"Huang","year":"2018","journal-title":"Asian J. Surg."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119252_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.119252_bib6","article-title":"Melittin promotes dexamethasone in the treatment of adjuvant rheumatoid arthritis in rats","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119252_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-003-0759-9","article-title":"Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine","volume":"53","author":"Wang","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119252_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/14737140.5.5.759","article-title":"Thalidomide and dexamethasone: therapy for multiple myeloma","volume":"5","author":"Kumar","year":"2005","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119252_bib9","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-05-2085","article-title":"Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells","volume":"12","author":"Yano","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119252_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3892\/ol.2016.5422","article-title":"Inhibitory effect of dexamethasone on residual Lewis lung cancer cells in mice following palliative surgery","volume":"13","author":"Sun","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119252_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12871-023-02277-9","article-title":"Dexamethasone inhibits IL-8 via glycolysis and mitochondria-related pathway to regulate inflammatory pain","volume":"23","author":"He","year":"2023","journal-title":"BMC Anesthesiol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119252_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/life14060725","article-title":"Switching to an intravitreal dexamethasone implant after intravitreal Anti-VEGF therapy for diabetic macular edema: a review","volume":"14","author":"Vitiello","year":"2024","journal-title":"Life"},{"issue":"Suppl 5","key":"10.1016\/j.ejmech.2026.119252_bib13","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119252_bib14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2217\/pgs-2017-0034","article-title":"Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate","volume":"18","author":"Rizzuto","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119252_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ajhp\/54.2.162","article-title":"Gemcitabine: a cytidine analogue active against solid tumors","volume":"54","author":"Hui","year":"1997","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119252_bib16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2174\/092986712799320682","article-title":"Gemcitabine: a critical nucleoside for cancer therapy","volume":"19","author":"Gesto","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119252_bib17","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.ejmech.2026.119252_bib18","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119252_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdl395","article-title":"Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma","volume":"18","author":"Morschhauser","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.119252_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119252_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216382","article-title":"Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: special focus on resistance mechanisms and metronomic therapies","volume":"573","author":"Natu","year":"2023","journal-title":"Cancer Lett."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2026.119252_bib22","article-title":"Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: environmental factors, molecular profile and drug\/nanotherapeutic approaches","volume":"240","author":"Ashrafizadeh","year":"2024","journal-title":"Environ. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119252_bib23","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1002\/jps.24629","article-title":"Semi-mechanism-based pharmacokinetic\/pharmacodynamic model for the combination use of dexamethasone and gemcitabine in breast cancer","volume":"104","author":"Yuan","year":"2015","journal-title":"J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119252_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:06:05Z","timestamp":1793977565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"alternative-id":["S0223523426006975"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119252","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of novel gemcitabine-dexamethasone hybrid as potent antitumor agents against esophageal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119252"}}